For the quarter ending 2026-03-31, CPIX made $9,131,317 in revenue. -$3,289,639 in net income. Net profit margin of -36.03%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net revenues | 9,131,317 | 15,816,928.5* | 8,292,362 | 10,837,363 |
| Cost of products sold | 1,933,889 | 2,166,983.5* | 988,760 | 2,011,389 |
| Selling and marketing | 5,064,875 | 6,111,936* | 4,433,831 | 4,223,647 |
| Research and development | 1,458,436 | 1,483,849* | 1,253,367 | 1,468,399 |
| General and administrative | 2,554,475 | 3,776,427* | 2,572,066 | 2,874,922 |
| Amortization | 1,248,934 | 1,010,534* | 1,009,598 | 1,006,484 |
| Total costs and expenses | 12,260,609 | 14,549,729.5* | 10,257,622 | 11,584,841 |
| Operating income (gain) | -3,129,292 | 1,267,199* | -1,965,260 | -747,478 |
| Interest income | 78,031 | 88,140* | 131,583 | 127,489 |
| Other income - gain on insurance proceeds | - | 0* | 0 | - |
| Interest expense | 85,839 | 167,121* | 109,699 | 109,547 |
| Loss before income taxes | - | - | -1,943,376 | -729,536 |
| Income (loss) before income taxes | -3,137,100 | 1,188,218* | - | - |
| Income tax expense | 3,871 | 23,244.5* | 5,670 | 5,671 |
| Co-commercialization investment loss | -146,080 | -3,305* | - | - |
| Net income (gain) | -3,287,051 | 1,161,668.5* | -1,949,046 | -735,207 |
| Net loss (income) at subsidiary attributable to noncontrolling interests | 2,588 | -24,459.5* | -8,282 | 5,533 |
| Net income (gain) attributable to common shareholders | -3,289,639 | 1,186,128 | -1,940,764 | -740,740 |
| Basic EPS | -0.22 | 0.081 | -0.13 | -0.05 |
| Diluted EPS | -0.22 | 0.081 | -0.13 | -0.05 |
| Basic Average Shares | 14,960,210 | 14,644,727 | 14,958,534 | 14,960,596 |
| Diluted Average Shares | 14,960,210 | 14,644,727 | 14,958,534 | 14,960,596 |
CUMBERLAND PHARMACEUTICALS INC (CPIX)
CUMBERLAND PHARMACEUTICALS INC (CPIX)